Savant Capital LLC Trims Stock Position in United Therapeutics Corporation $UTHR

Savant Capital LLC reduced its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 84.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,863 shares of the biotechnology company’s stock after selling 9,881 shares during the quarter. Savant Capital LLC’s holdings in United Therapeutics were worth $908,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Torren Management LLC purchased a new stake in shares of United Therapeutics in the 4th quarter worth about $26,000. Activest Wealth Management grew its position in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the period. Entrust Financial LLC purchased a new stake in shares of United Therapeutics in the 4th quarter worth about $31,000. Wilmington Savings Fund Society FSB grew its position in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. purchased a new stake in shares of United Therapeutics in the 4th quarter worth about $48,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $540.05 on Wednesday. The stock has a market cap of $22.93 billion, a price-to-earnings ratio of 19.94, a PEG ratio of 1.77 and a beta of 0.57. The firm’s 50-day moving average is $566.86 and its 200 day moving average is $516.87. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.63 EPS. On average, equities analysts expect that United Therapeutics Corporation will post 26.92 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on UTHR. Bank of America upped their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research report on Thursday, May 7th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. UBS Group upped their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Finally, Raymond James Financial assumed coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $9,956,712.48. This represents a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have sold 614,043 shares of company stock worth $344,991,997. 8.60% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.